Navigation Links
Orally Disintegrating Tablets and Thin Films Poised to See Strong Growth
Date:4/18/2013

FALLS CHURCH, Va., April 18, 2013 /PRNewswire/ -- Orally disintegrating tablets (ODTs) are coming into their own as mainstream pharmaceutical products.  Oral thin films (OTFs) have also come into strong prominence with the launch of Suboxone® (buprenorphine and naloxone) thin films demonstrating a huge potential for thin films in prescription products.  Statistics have shown that four out of five patients prefer orally disintegrating dosage forms over conventional solid oral dosages.  These factors, coupled with convenience and compliance advantages, have been (and will continue to) pave the way for ODT and OTF drug product growth.

During a recent interview with Technology Catalysts, Bob Duffy , Marketing Manager, Excipients & Drug Delivery Systems for SPI Pharma, a leading developer of ODT formulations using its Pharmaburst® technology, stated, "Due to advances in various drug delivery technologies, of which SPI's Pharmaburst direct-compression platform is a market leader, ODTs are no longer only for treating niche therapeutic areas.  With improvements in mouthfeel, disintegration time, and the ability to handle higher drug loading, the ODT market is on the verge of becoming mainstream in a variety of both prescription and OTC medications for treating pain, cough/cold, sleep disorders, GERD, and ED."

The OTF market has received a huge boost with the phenomenal success of Reckitt Benckiser's prescription thin film, Suboxone.  Suboxone scored sales of $513 million in 2011 and accounted for 96 percent of the OTF market.  The success of this product demonstrates an increasing consumer acceptance of thin films as well the ability of pharmaceutical companies to successfully use thin films for lifecycle management. 

The ODT and OTF markets are discussed in depth in Technology Catalysts International's latest report, Orally Disintegrating Tablet and Film Technologies – Seventh Edition.  Key information presented in the report includes the growing Japanese generic market, ODTs in the emerging markets, ODT and OTF pipeline analysis, innovative developments for delivery of proteins and peptides via ODTs and OTFs, and new nutraceutical thin film technologies and products.

The report also includes a market analysis of both ODTs and OTFs, sales of leading ODT products in 2010-2011, ODT brand erosion by generics, late stage prescription OTFs, and the sales potential for OTFs with key APIs.  Most importantly, the report contains screened and confirmed business and technology licensing opportunities from around the globe.

For complete report prospectus, pricing, and ordering information, please refer to:

http://www.technology-catalysts.com/reports_services/odt7.asp

About Technology Catalysts International:

Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research. The company specializes in technology licensing, technology assessment, and business intelligence. With a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes, TCI's core consulting services are based on continuous monitoring of technological product development activities on a global basis.  TCI is headquartered in the US and has offices in the UK, Germany, Czech Republic, China, Korea, Japan, India, and Latin America.

Contact:

Ajay Rastogi , Vice President
Technology Catalysts International
Telephone (703) 531-0257
arastogi@technology-catalysts.com
http://www.technology-catalysts.com


'/>"/>
SOURCE Technology Catalysts International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally
2. Mylan Launches Generic Version of Zyprexa® Tablets
3. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
4. Mylan Launches Generic Version of Plavix® Tablets
5. Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
6. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
10. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
11. Qualitest Receives FDA Approval for Levetiracetam Extended-Release Tablets, 500mg and 750mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... , August 17, 2017 DarioHealth ... Company with mobile health and big data solutions, ... agreements with domestic and non-U.S. investors for the ... and shares of the Company,s newly designated Series ... offerings. The Company expects to conduct a closing ...
(Date:8/15/2017)... HOUSTON , Aug. 15, 2017   Mostyn Law ... in Houston, Texas . The Mostyn Law ... the past 2 years. That is why Mostyn Law ... Texas to show its appreciation. Blood supplies ... to fall 5% short of hospital needs in August. That is ...
(Date:8/15/2017)... Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the drug ... in the beginning stages of an IPO. The ... with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, a ... communities in North-Central West Virginia, is embarking on a cooperative charity effort with ... area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for ...
(Date:8/18/2017)... ... 2017 , ... The Brian Gifford Agency, an Indiana-based firm providing asset protection ... Campagna Academy in a charity drive to provide for at-risk children and teens in ... Academy is a nonprofit organization that has offered critical programs to at-risk and foster ...
(Date:8/18/2017)... ... 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the memo ... Generation Mindful. To help change the mindset of parents and educators from punitive to ... the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in ...
(Date:8/18/2017)... ... 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the body of ... its product now available through Jet.com. , After 25 years of development, the ... is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having ...
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: ... faith they shared to overcome struggles in life. “Our Mountains to Climb: A Journey ... Corcoran, a retired teacher and happily married since 1999; the author’s personal experiences drive ...
Breaking Medicine News(10 mins):